Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (6967)	8/22/1998 8:53:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

I find this interesting: marketgauge.com up to date charts on: Market Momentum: NY Stock Exchange 5-Day Advance/Decline Oscillator NY Stock Exchange 3-Day Up/Down Volume Ratio NY Stock Exchange 12-Day Advance/Decline Oscillator NY Stock Exchange 5-Day Up/Down Volume Ratio NY Stock Exchange Advance/Decline 10-Day Rate of Change NY Stock Exchange 10-Day Up/Down Volume Ratio NY Stock Exchange 30-Day Advance/Decline Oscillator NY Stock Exchange New High/New Low Ratio NASDAQ 5-Day Advance/Decline Oscillator NASDAQ 3-Day Up/Down Volume Ratio NASDAQ 12-Day Advance/Decline Oscillator NASDAQ 5-Day Up/Down Volume Ratio NASDAQ 30-Day Advance/Decline Oscillator NASDAQ New High/New Low Ratio Value Line 5% Swing Model Value Line Moving Average Convergence/Divergence Indicator Contrary Opinion: OEX Put/Call One Day Ratio OEX Put/Call Five Day Ratio CBOE Put/Call Premium Ratio AAII Sentiment Index Ratio Mutual Fund Cash Levels Closed-End Fund % Discount to Net Asset Value NY Stock Exchange Short Interest Ratio Deviation Monetary Conditions: Federal Funds 3 Month Rate of Change Treasury Bills 3 Month Rate of Change 30 Yr. T-Bond 6 month Rate of Change Yield Curve Slope Discount Rate Model Fundamental Factors: S&P 500 Price Earnings Ratio S&P 500 Dividend Yield vs. Treasury-Bill Yield S&P 500 Earnings Yield vs. Treasury-Bill Yield 30 Yr. T-Bond Yield Minus Dividend Yield Earnings Growth - Change in Bond Yield Smart Money: Vicker's Insider 8 Week Sell/Buy Ratio Specialists and Members Short Positions

To: Bluegreen who wrote (6967)	8/22/1998 8:54:00 AM
From: Tharos	Respond to of 17367

PC shipments fall steeper than forecast in region IDC study says Singapore shipments in Q2 down 19.2% year on year business-times.asia1.com.sg

To: Bluegreen who wrote (6967)	8/22/1998 6:53:00 PM
From: Tharos	Respond to of 17367

Short interest holding pretty much where it has been since the first of the year. Will be interesting to see if recent financing deal caused a significant increase in shorts in Aug. 07/98 1,207,241 174,044 6.94 06/98 1,135,690 172,763 6.57 05/98 1,387,323 301,479 4.60 04/98 1,257,713 244,490 5.14 03/98 1,253,019 253,521 4.94 02/98 1,047,833 182,145 5.75 01/98 1,041,636 275,796 3.78 12/97 843,006 165,795 5.08 11/97 739,787 407,644 1.81 10/97 605,955 406,461 1.49 09/97 497,856 647,231 0.77 08/97 497,408 454,824 1.09

To: Bluegreen who wrote (6967)	8/22/1998 7:16:00 PM
From: Tharos	Read Replies (1) \| Respond to of 17367

Some time ago, on another thread, one of those types that likes to point out perceived errors in other's postings yet never really contributes anything to the conversation, queried about the differences between US and UK drug approval. I poked around various UK ministries' sites and never found anything as nice as the FDA's guidance. Did; however, find this. A bit dated: Office of Planning and Evaluation Approval of New Drugs in the United States Comparison With the United Kingdom, Germany and Japan David A. Kessler MD, JD; Arthur E. Hass; Karyn L. Feiden; Murray Lumpkin, MD; Robert Temple, MD Originally published in Journal of the American Medical Association, December 11, 1996 - Vol 276, No. 22 Abstract The marketing approval dates of 214 drugs newly introduced into the world market from January, 1990 through December, 1994 were compared in 4 countries. The analysis reveals that the United States and the United Kingdom have similar patterns of drug availability, although the United States has a number of therapies with significant public health benefits that are not yet available in the United Kingdom. The findings also show that the United States outpaces both Germany and Japan in approving important new drugs. Various strategies adopted by the Food and Drug Administration to expedite its pharmaceutical review process, including the use of industry user fees, are described. For a reprint of the JAMA article, write to: Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. The Database A link to the complete database used to compare recent new drug approval activity in the United States, the United Kingdom, Germany and Japan is provided here to allow subset analyses. The data is in a fixed width font (Courier) and can be cut and pasted into any text reader or a spreadsheet for analysis. The first column (NEW DRUG NAME) in the table identifies the name of the drug as reported by Scrip World Pharmaceutical News or Scrip Magazine and includes occasional notes. The list is sorted alphabetically by drug name within five groupings -- the frequency of approval (0, 1, 2, 3, 4) among the four countries studied. The second column (PRIORITY ?) identifies those drugs which the FDA classified as priority review. The third column (1ST MKT) identifies the country where the drug was first marketed as reported by Scrip World Pharmaceutical News or Scrip Magazine. The fourth column (SCRIP YEAR) identifies the calendar year in which the drug was first marketed as reported by Scrip World Pharmaceutical News or Scrip Magazine. Column five (NUMBER OF APPROVALS) notes the number of approvals for each drug among the four countries studied as of April 1995. Columns six through nine (USA DATE, etc.) report the approval date for each of the four countries studied where applicable. The most specific information provided by the various regulatory authorities is reported. This information was sufficient to determine rank order of approval in all cases. Columns ten through 13 (USA RANK, etc.) identify the rank order of approval for each drug among the four countries studied. SI did not like posting database, database can be found at: fda.gov